Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

By B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, F. van Rhee, A. Fassas, M. Zangari, K. Hollmig, M. Pineda‐Roman and 7 more. New England Journal of Medicine, 2006

742 citations recorded by the source corpus.

Subfields: Hematology, Oncology, Plant Science

View Paper: https://www.semanticscholar.org/paper/92a1563898e0f77b631b00f0966a7f968355002a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar

In Oncology

1. Giuseppe Jurman
2. Charles Dumontet
3. S. Rajkumar

In Plant Science

1. Joaquín Dopazo
2. Tieliu Shi
3. Baitang Ning
4. Mauro Delorenzi

Citations in the corpus

• The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models (2010, background): “Gene expression profiling of highly purified bone marrow plasma cells was performed in newly diagnosed patients with M”
• Chemotherapy‐induced peripheral neurotoxicity: A critical analysis (2013, background): “Trials have identified that neuropathic symptoms typically improved within 3 to 4 months after the cessation of thalidomide treatment in 90% of patients.(194) However, studies in patients with other disorders who were treated with thalidomide for more than 2 years have suggested limited and slow rev”
• Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. (2006, background): “The probability of event-free survival (95% CI) after randomization at 2 years, 3 years, and 4 years with thalidomide is 71 (63-78), 52 (43-62), and 36 (22-55), respectively, and without thalidomide is 58 (53-64), 37 (31-44), and 26 (14-41), respectively.”